Modality
Gene Editing
MOA
STINGag
Target
AHR
Pathway
Incretin
WMADHD
Development Pipeline
Preclinical
~Apr 2012
→ ~Jul 2013
Phase 1
~Oct 2013
→ ~Jan 2015
Phase 2
~Apr 2015
→ ~Jul 2016
Phase 3
~Oct 2016
→ ~Jan 2018
NDA/BLA
~Apr 2018
→ ~Jul 2019
Approved
Oct 2019
→ May 2028
ApprovedCurrent
NCT06428349
2,798 pts·WM
2019-10→2028-05·Completed
2,798 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2028-05-202.1y awayPh3 Readout· WM
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Approved
Complet…
Catalysts
Ph3 Readout
2028-05-20 · 2.1y away
WM
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06428349 | Approved | WM | Completed | 2798 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| RHH-5389 | Roche | Preclinical | RET | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |